30/07/2015 09:12:24 Cookie Policy Free Membership Login

Alliance Pharma Share Chat - APH

Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00 +0.00% 54.25 53.50 55.00 54.25 54.25 54.25 9,770 07:51:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 43.5 10.2 3.2 17.1 143.33

Alliance Pharma Share Discussion Threads

Showing 1200 to 1225 of 1225 messages
Post New Message
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  >>
DateSubjectAuthorDiscuss
27/7/2015
13:50
Another stream of buys today, including now at 54.5p. Perhaps another acquisition/deal is on the way.rivaldo
24/7/2015
17:39
APH has held up surprisingly well over the 2 weeks following several small intra-day dips as 'profit-taking' inevitably occurred. It may be worth remembering that APH steadily declined to below 34p in March this year before staging a dramatic recovery and todays share price represents a hefty 53% gain on that position. So many 'shorter term' holders may find current levels hard to ignore. So far there has appeared to be a buyer or buyers in the back ground who were prepared to 'mop up' and reinstate the rising trend, but IMV this situation can't last indefinitely. APH has seen many significant 'breakouts' in the past that have fizzled out for one reason or another and the share price drifted back down for want of news etc. As a long term holder I am keen to know exactly what lies behind the latest move upwards as the prospects for APH in March were just as valid then as they are now. The latest share price surge could well draw comment from analysts.mazarin
23/7/2015
14:09
Nice 94k buy at 53p early this morning, a full 1p above the 52p offer price at the time. Very keen.rivaldo
22/7/2015
07:30
Comment from Robbie Burns last week will have helped the price no doubt: Alliance Pharma (APH) looks an interesting pharma with a good pipeline. It didn't have a very good 2014 but statements but recent statements show a much more bullish tone for 2015 and 2016 and the price is rising nicely in response. Obviously pharmas do carry some risk but I like the risk-reward ratio here and happy to pick some up. It's one of those that could be a massive winner given time. It seems to have a winner in Hydromol performing well.cisk
21/7/2015
18:17
Very good run on this - suddenly in play.capercaillie
21/7/2015
10:31
I have not seen such positive and sustained 'action' here before without grounds or any news' supportive feed and am equally surprised that no RNS has been issued to indicate change of Interest or Holding.mazarin
21/7/2015
10:31
This share price action is either Mr Market getting overly excited or APH have lined up another GBP50-100m type deal that I understand was on previously on the cards but never got to the finish line. Such a transformational deal could make 50p look cheap. Guess we will have to wait and see...norbert colon
21/7/2015
09:38
APH now bid as you like at the mid-price. Only 2000 on offer on the rsp. Looks like another leg up is on the cards. GLAroper
20/7/2015
11:17
Good summary Norbert in post 571, nothing to add really. Buying coming in at 49p now.rivaldo
15/7/2015
10:18
Whatever it is, there is no denying that there is a buyer about willing to pay current, rising prices - a buyer who clearly recognises value to be unlocked even from these all time high prices. Congratulations to the company and all patient holders.pimpernel4
15/7/2015
10:13
Thanks Norbert, I essentially see it the same way and have real expectation that ImmuCyst in particular has the potential to make quite a contribution to the figures when full production resumes. Its sudden loss a few years ago following Sinofi's disaster certainly had a significant impact on APH's profits and it looks like that's behind them now. However I do appreciate that APH has to recover some of its lost market share from competitors who moved in to fill the gap.mazarin
15/7/2015
08:38
Maz My thoughts on the price rise / re-rating: - Seen as a growth share again after last few years malaise - ImmuCyst coming back on line after a long wait - profitable product - More deals likely - possibly a big(ger) one - Possibility of being a bid target themselves All of that said, the strong re-rating has come as a surprise but thats Mr Market for you - exuberance / depression - repeat.norbert colon
14/7/2015
23:40
I believe at 46.5p APH achieved an 'all time high' today. It's certainly the highest since I first bought into it over 16 yrs ago and am really intrigued to know what's currently driving it. I can only assume that there must be some hint of an acquisition somewhere on the horizon or may be it has simply been discovered by a new generation of investors? See a recent comment following pre-close update: http://tinyurl.com/owb7vj5mazarin
14/7/2015
11:30
Cheers hastings. Here's the Private Punter's article which may generate some further interest: Http://www.cambridge-news.co.uk/Private-Punter-Alliance-Pharama-offers-good/story-26897586-detail/story.html Conclusion: "Additional upside potential for Alliance may also be driven by further bolt on acquisitions, where the company has already demonstrated a strong track record. No less than 26 deals have been completed over a 15 year period, which has resulted in the company delivering improved profitability along with a progressive dividend policy where, with a forecast 1.2p for 2015, it provides an additionally welcome, but modest yield of 2.2%. For now, broker Numis is anticipating revenues of £48m for next year, rising to £51m by 2017, which could deliver pre-tax profits of £13.1m. That would see EPS of 3.8p, implying a longer term PER of 11 against the current 13, which suggests decent value in a sector average of close to 16. There are some notable holders of Alliance's shares, including the respected Nigel Wray, who heads with a 15% stake, while institutions of note are Aviva, Artemis and Slater Investments. Also of interest is the very recent announcement that the highly experienced Andrew Franklin, who was FD at Genzyme, will be taking up the role of Group FD in September."rivaldo
13/7/2015
18:28
May be of interest. http://www.privatepunter.co.uk/Companies/two-for-this-week-13-july-2015hastings
13/7/2015
07:42
For further info on PPRS as mentioned in today's Pre-Close Update see: http://tinyurl.com/qfbyqsmmazarin
10/7/2015
08:19
Riv Yes I agree. I am also pleased that the appointment is in place as Richard's departure as FD was discussed at the AGM and it was key that they got someone else in quickly to avoid any uncertainty etc. Onward and upward.norbert colon
10/7/2015
07:16
News today. I wouldn't normally comment on the appointment of a new FD, but APH's new FD is certainly worth noting, being the ex-UK FD of Genzyme, and prior to that of Wyeth. A very impressive appointment for a relative minnow like APH: Http://www.investegate.co.uk/alliance-pharma-plc--aph-/rns/appointment-of-finance-director/201507100700096601S/rivaldo
08/7/2015
14:50
Riv Yes, that dip to 39p was again another great chance to get on board and the big bounce back up has been surprisingly strong. There is a lot of potential here with acquisitions going forward and I really struggle to ever find something I don't like which I very comforting. I really intend for this to be a long term hold for me and wish us both all the best!norbert colon
08/7/2015
14:30
Norbert, looks like our timeframe may have to be adjusted :o))rivaldo
06/7/2015
07:42
This tip in Money Week hasn't been posted here: Http://moneyweek.com/money-morning-aim-stocks-bargains/ "Alliance Pharma (Aim: APH) is one example of an Aim stock that we think has promise. Its business model is based on picking up established but less well-known drugs that it thinks are undervalued by their companies, with a view to getting the maximum amount of money from them. It has a portfolio covering over 50 treatments, and specialises in cancer and dermatology drugs. In April it bought MacuVision, which has a successful treatment for macular degeneration, an age-related eye problem. Despite the fact that Alliance Pharma’s share price has risen by over 20% since we last tipped it in November, it still trades at only 10.3 times forecast 2016 earnings."rivaldo
02/7/2015
10:37
Riv As a long term shareholder and accumulator on the dips I think you have made a good purchase with a suitable medium / long term timeframe.norbert colon
02/7/2015
08:45
I picked some of these up on the dip at just above 38p, so going pretty well to date. I liked the look of the company when I saw them present a while back. Should be a nice solid long-termer, with room for sudden jumps in forecasts and the share price on further company or product acquisitions.rivaldo
02/7/2015
08:28
Is something 'cooking' here, as there have been a series of steady buy's going through over the last few days that's suggesting someone, somewhere is in the know....? May have some connection to my Post 552mazarin
Chat Pages: 49  48  47  46  45  44  43  42  41  40  39  38  >>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 150730 09:12